BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9678794)

  • 21. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
    Andrews RG; Briddell RA; Hill R; Gough M; McNiece IK
    Stem Cells; 1999; 17(4):210-8. PubMed ID: 10437984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
    Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
    Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors.
    Kozuka T; Ikeda K; Teshima T; Yoshida C; Shinagawa K; Kojima K; Matsuo K; Bessho A; Sunami K; Hiramatsu Y; Maeda Y; Noguchi T; Yamamoto K; Fujii N; Imai T; Kusumoto KK; Masuda K; Takenaka K; Ishimaru F; Niiya K; Koide N; Tanimoto M; Harada M
    Transfusion; 2004 Apr; 44(4):526-32. PubMed ID: 15043568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease.
    Madero L; González-Vicent M; Molina J; Madero R; Quintero V; Díaz MA
    Bone Marrow Transplant; 2000 Aug; 26(4):365-9. PubMed ID: 10982281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
    Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
    Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mobilization of peripheral blood progenitor cells using 16 versus 10 mg/kg/d G-CSF in children with malignancies.
    Kurekci AE; Kiss JE; Koehler M
    Pediatr Transplant; 1998 May; 2(2):160-4. PubMed ID: 10082450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
    Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
    Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
    Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective.
    Faulkner LB; Tucci F; Tamburini A; Tintori V; Lippi AA; Bambi F; Malentacca F; Azzari C; Gelli AM; Genovese F; Bernini G
    Bone Marrow Transplant; 1998 Jun; 21(11):1091-5. PubMed ID: 9645570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
    Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
    Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study.
    Basara N; Schmetzer B; Blau IW; Bischoff M; Günzelmann S; Kirsten D; Fauser AA
    Bone Marrow Transplant; 2000 Feb; 25(4):371-6. PubMed ID: 10723579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.